Canaccord Genuity has recently initiated Vericel Corp (VCEL) stock to Buy rating, as announced on August 9, 2024, according to Finviz. Earlier, on June 20, 2024, TD Cowen had initiated the stock to Buy, setting a price target of $55. Truist also raised Buy rating with a price target of $51. Additionally, BTIG Research raised Buy rating on August 8, 2023, with a target price of $39. BTIG Research analysts, in their report published on November 10, 2022, also reduced Neutral rating for Vericel Corp’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Vericel Corp (VCEL) Stock Trading Recap
On Tuesday, Vericel Corp (VCEL) stock saw a decline, ending the day at $47.81 which represents a decrease of $-1.04 or -2.13% from the prior close of $48.85. The stock opened at $49.1 and touched a low of $46.86 during the day, reaching a high of $49.1. The volume of shares traded was 0.34 million falling short of the average volume of 0.40 million.
Sponsored
VCEL Stock Performance and Moving Averages
In recent trading, Vericel Corp (VCEL) stock price has shown some volatility, fluctuating -6.51% over the last five trades and -18.06% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 5.73%, and it has plunged by -15.41% in the previous three months. Currently, VCEL is trading at -9.33%, -14.77%, and -4.87% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, VCEL, a Healthcare sector stock, is trading -24.11% below its 52-week high but remains 22.21% above its 52-week low. The Average True Range (ATR) (14 days) of 2.58 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Vericel Corp’s Profitability and Valuation Ratios
Vericel Corp’s profitability metrics reveal financial health. The company currently boasts an operating margin of 1.90% and a profit margin of 4.37%, with a gross margin of 5.73%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Vericel Corp’s market capitalization stands at $2.39 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 258.99, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 64.43. Additionally, the Price-to-Sales Ratio is 10.07, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 8.13, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.05% of Vericel Corp (VCEL)’s shares, while financial institutions hold 105.19%.
Notable insider trades include Halpin Michael, Chief Operating Officer at Vericel Corp (VCEL), who sold 10,000 shares on Mar 03 ’25, at $49.52 each, totaling $0.50 million. On Mar 03 ’25, Hagen Heidi, Director, sold 9,000 shares for $49.53 each, amounting to $0.45 million. Additionally, on Mar 03 ’25, Mara Joseph Anthony Jr sold 9,000 shares at $49.53 each, generating $0.45 million.
